Marco Castagneto

Keyron Ltd. is a preclinical-stage medical device and technology platform company based in Italy. The company is backed by multiple institutional investors based in the USA and EMEA. The company is based in Italy. The British company aims to provide a highly-effective treatment for metabolic diseases such as type-2 diabetes, NASH, and obesity. Keyron's patented Forepass™ is an innovative medical device that has already demonstrated a full reversal of insulin resistance in animal studies. The company has upcoming clinical trials in Europe and aims to carry out further clinical trials in the USA. Keyron's founders, directors, advisors, and investors include some of the most well-known and cited professors and KOLs worldwide in the metabolic diseases space. The company was founded in 2016 by Giorgio Castagneto Gissey and Marco Castagneto. Carl D. Francis has been the CEO of the company since 2023.

Keyron Ltd. is a preclinical-stage medical device and technology platform company based in Italy. The company is backed by multiple institutional investors based in the USA and EMEA. The company is based in Italy. The British company aims to provide a highly-effective treatment for metabolic diseases such as type-2 diabetes, NASH, and obesity. Keyron's patented Forepass™ is an innovative medical device that has already demonstrated a full reversal of insulin resistance in animal studies. The company has upcoming clinical trials in Europe and aims to carry out further clinical trials in the USA. Keyron's founders, directors, advisors, and investors include some of the most well-known and cited professors and KOLs worldwide in the metabolic diseases space. The company was founded in 2016 by Giorgio Castagneto Gissey and Marco Castagneto. Carl D. Francis has been the CEO of the company since 2023.

Keyron Ltd. is a preclinical-stage medical device and technology platform company based in Italy. The company is backed by multiple institutional investors based in the USA and EMEA. The company is based in Italy. The British company aims to provide a highly-effective treatment for metabolic diseases such as type-2 diabetes, NASH, and obesity. Keyron's patented Forepass™ is an innovative medical device that has already demonstrated a full reversal of insulin resistance in animal studies. The company has upcoming clinical trials in Europe and aims to carry out further clinical trials in the USA. Keyron's founders, directors, advisors, and investors include some of the most well-known and cited professors and KOLs worldwide in the metabolic diseases space. The company was founded in 2016 by Giorgio Castagneto Gissey and Marco Castagneto. Carl D. Francis has been the CEO of the company since 2023.

Keyron Ltd. is a preclinical-stage medical device and technology platform company based in Italy. The company is backed by multiple institutional investors based in the USA and EMEA. The company is based in Italy. The British company aims to provide a highly-effective treatment for metabolic diseases such as type-2 diabetes, NASH, and obesity. Keyron's patented Forepass™ is an innovative medical device that has already demonstrated a full reversal of insulin resistance in animal studies. The company has upcoming clinical trials in Europe and aims to carry out further clinical trials in the USA. Keyron's founders, directors, advisors, and investors include some of the most well-known and cited professors and KOLs worldwide in the metabolic diseases space. The company was founded in 2016 by Giorgio Castagneto Gissey and Marco Castagneto. Carl D. Francis has been the CEO of the company since 2023.

Keyron Ltd. is a preclinical-stage medical device and technology platform company based in Italy. The company is backed by multiple institutional investors based in the USA and EMEA. The company is based in Italy. The British company aims to provide a highly-effective treatment for metabolic diseases such as type-2 diabetes, NASH, and obesity. Keyron's patented Forepass™ is an innovative medical device that has already demonstrated a full reversal of insulin resistance in animal studies. The company has upcoming clinical trials in Europe and aims to carry out further clinical trials in the USA. Keyron's founders, directors, advisors, and investors include some of the most well-known and cited professors and KOLs worldwide in the metabolic diseases space. The company was founded in 2016 by Giorgio Castagneto Gissey and Marco Castagneto. Carl D. Francis has been the CEO of the company since 2023.